Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stebbins

Showing results (1041-1050 of 1,116) with videos related to

Pageof 112
Sort By:
Stem Cells Translational Medicine|August 26, 2020
Magnetic resonance imaging of human neural stem cells in rodent and primate brainLisa M McGinley, Matthew S Willsey, Osama N Kashlan, et al.
Journal of Parkinson'S Disease|May 22, 2023
Mapping Relevance of Digital Measures to Meaningful Symptoms and Impacts in Early Parkinson's DiseaseJennifer R Mammen, Rebecca M Speck, Glenn M Stebbins, et al.
Open Heart|March 14, 2018
Six-minute walk distance after coronary artery bypass grafting compared with medical therapy in ischaemic cardiomyopathyRalph A H Stewart, Dominika Szalewska, Amanda Stebbins, et al.
Journal of Neurology|August 7, 2012
Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)Pablo Martinez-Martin, Carmen Rodriguez-Blazquez, Mario Alvarez-Sanchez, et al.
Journal of Parkinson'S Disease|May 22, 2023
Relative Meaningfulness and Impacts of Symptoms in People with Early-Stage Parkinson's DiseaseJennifer R Mammen, Rebecca M Speck, Glenn T Stebbins, et al.
Movement Disorders Clinical Practice|October 27, 2018
Turkish Standardization of Movement Disorders Society Unified Parkinson's Disease Rating Scale and Unified Dyskinesia Rating ScaleMuhittin C Akbostanci, Ece Bayram, Volkan Yilmaz, et al.
Epilepsy Research|August 24, 2010
Predicting white matter targets for direct neurostimulation therapyMarvin A Rossi, Glenn Stebbins, Christopher Murphy, et al.
Expert Opinion on Investigational Drugs|August 20, 2011
Targeting Mcl-1 for the therapy of cancerBridget A Quinn, Rupesh Dash, Belal Azab, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 17, 2010
Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonistJ S Swaney, C Chapman, L D Correa, et al.
Neuroscience and Biobehavioral Reviews|May 4, 2023
Understanding visual hallucinations: A new synthesisDaniel Collerton, James Barnes, Nico J Diederich, et al.
Pageof 112

Showing results (1041-1050 of 1,116) with videos related to

Sort By:
Pageof 112
Stem Cells Translational Medicine|August 26, 2020
Magnetic resonance imaging of human neural stem cells in rodent and primate brainLisa M McGinley, Matthew S Willsey, Osama N Kashlan, et al.
Journal of Parkinson'S Disease|May 22, 2023
Mapping Relevance of Digital Measures to Meaningful Symptoms and Impacts in Early Parkinson's DiseaseJennifer R Mammen, Rebecca M Speck, Glenn M Stebbins, et al.
Open Heart|March 14, 2018
Six-minute walk distance after coronary artery bypass grafting compared with medical therapy in ischaemic cardiomyopathyRalph A H Stewart, Dominika Szalewska, Amanda Stebbins, et al.
Journal of Neurology|August 7, 2012
Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)Pablo Martinez-Martin, Carmen Rodriguez-Blazquez, Mario Alvarez-Sanchez, et al.
Journal of Parkinson'S Disease|May 22, 2023
Relative Meaningfulness and Impacts of Symptoms in People with Early-Stage Parkinson's DiseaseJennifer R Mammen, Rebecca M Speck, Glenn T Stebbins, et al.
Movement Disorders Clinical Practice|October 27, 2018
Turkish Standardization of Movement Disorders Society Unified Parkinson's Disease Rating Scale and Unified Dyskinesia Rating ScaleMuhittin C Akbostanci, Ece Bayram, Volkan Yilmaz, et al.
Epilepsy Research|August 24, 2010
Predicting white matter targets for direct neurostimulation therapyMarvin A Rossi, Glenn Stebbins, Christopher Murphy, et al.
Expert Opinion on Investigational Drugs|August 20, 2011
Targeting Mcl-1 for the therapy of cancerBridget A Quinn, Rupesh Dash, Belal Azab, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 17, 2010
Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonistJ S Swaney, C Chapman, L D Correa, et al.
Neuroscience and Biobehavioral Reviews|May 4, 2023
Understanding visual hallucinations: A new synthesisDaniel Collerton, James Barnes, Nico J Diederich, et al.
Pageof 112